Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?

Nichole Bevel, Meagan Thorpe, Thiru Vanniasinkam

Research output: Contribution to journalArticlepeer-review

35 Downloads (Pure)

Abstract

Certain therapies that target CD markers on some blood cells can affect pretransfusion testing. Key examples are anti-CD38, CD47 monoclonal antibody (mAb) therapies such as daratumumab (DARA) and magrolimab, which have presented a challenge for transfusion medicine laboratories around the globe. Scientists have been faced with not only introducing a protocol to provide safe blood to patients but also investigating the most effective method to remove the pretransfusion pan-agglutinating interference caused. A number of papers in the last 5 years have reported on various methods to remove pretransfusion interference; however, most of these studies have been conducted only in a few countries. Most recent reviews on this topic have focused on techniques and reagents to remove pretransfusion interference, and dithiothreitol is currently the gold standard for removing DARA interference. However, it was clear from this review that while many laboratories have developed processes for addressing interference in pretransfusion testing, and DARA interference may not be a major issue, there are still laboratories around the world, that may not have adequately addressed this issue. In addition, the impact of mAb interference on widely used techniques such as flow cytometry is unclear.

Original languageEnglish
JournalVox Sanguinis
DOIs
Publication statusE-pub ahead of print - 07 May 2024

Fingerprint

Dive into the research topics of 'Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?'. Together they form a unique fingerprint.

Cite this